At the ESMO 2019 Congress, Byong Chul Cho, MD, PhD, Yonsei Cancer Center, Seoul, South Korea, discusses results from the phase 3 ATTRACTION-3 study, which showed improved OS and safety with nivolumab over chemotherapy for patients with previously treated esophageal squamous cell carcinoma.
Nivolumab Improves Survival Over Chemotherapy in Esophageal Squamous Cell Carcinoma